Sep 30 |
Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation
|
Sep 3 |
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
|
Aug 6 |
Cogent Biosciences GAAP EPS of -$0.59
|
Aug 6 |
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
|
Jun 27 |
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial
|
Jun 23 |
Cogent Biosciences: Inflection Year Directly Ahead
|
Jun 14 |
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
|
May 24 |
Cogent Bio spikes after updating late-stage data for lead asset
|
May 23 |
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
|
May 23 |
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
|